Sr. Marketing Analyst
Harrow
Summary
Delivers marketing analytics and reporting for all three franchises so Marketing and Sales can see what is creating demand and where to invest next.
Job description
Position Summary
Delivers marketing analytics and reporting for all three franchises so Marketing and Sales can see what is creating demand and where to invest next.
Core Responsibilities
- Build and maintain brand and campaign dashboards on Microsoft Fabric.
- Analyze prescription and claims data (e.g., IQVIA, Symphony, Komodo) for demand trends, new-to-brand Rx, share, and patient flow.
- Measure campaign and channel ROI, working with Digital Marketing on attribution.
- Analyze territory-level demand drivers with the franchise teams.
- Contribute to brand forecasts with Marketing and Finance.
- Build the sample-to-Rx analysis with the Lead, Sample Management & Compliance.
- Present findings and recommendations to marketing and commercial leadership.
Qualifications & Requirements
- Bachelor's degree in a quantitative field; 5+ years in pharma commercial analytics.
- Hands-on with third-party Rx and claims data.
- Advanced SQL and a BI tool (e.g., Power BI).
- Proficiency with AI platforms such as ChatGPT and Claude, and with Slack.
Preferred Qualifications
- Master's degree.
- Promotion response or marketing-mix modeling.
- Eye care analytics experience.
Requirements
- Bachelor's degree in a quantitative field
- 5+ years in pharma commercial analytics
- Hands-on with third-party Rx and claims data
- Advanced SQL
- BI tool experience (e.g., Power BI)
- Proficiency with AI platforms such as ChatGPT and Claude
- Proficiency with Slack
Company overview
Harrow Health, Inc. (NASDAQ: HROW) is a publicly traded pharmaceutical company headquartered in Nashville, Tennessee, specializing in ophthalmic healthcare solutions. Founded in 2012 and formerly known as Imprimis Pharmaceuticals, the company has established itself as a growing leader in the ophthalmic pharmaceutical market. Harrow operates through multiple subsidiaries including ImprimisRx, its compounding pharmacy business that produces cGMP ophthalmic eye drops and sterile compounded products. The company's core mission focuses on providing affordable and accessible medications while maintaining an unyielding dedication to innovation. Harrow gained significant attention for developing low-cost alternatives to expensive medications, most notably creating a $1 per pill alternative to Daraprim during the Martin Shkreli controversy. The company's business model emphasizes developing inexpensive alternatives to off-patent medicines where single manufacturers charge excessive prices. With a portfolio that includes branded, generic, and compounded ophthalmic medications, Harrow serves healthcare providers and patients across the United States through its FDA-registered outsourcing facilities and nationwide distribution network.